Overview

Study of BHV-3241 in Subjects With Multiple System Atrophy

Status:
Active, not recruiting

Trial end date:
2022-09-20

Target enrollment:
0

Participant gender:
All

Summary

The purpose of this study is to compare the efficacy of BHV-3241 versus placebo in subjects with Multiple System Atrophy

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Biohaven Pharmaceuticals, Inc.

Criteria

Inclusion Criteria:

1. Diagnosis of probable or possible MSA according to consensus clinical criteria (Gilman
et al 2008), including subjects with MSA of either subtype (MSA-P or MSA-C).

2. Able to ambulate without the assistance of another person, defined as the ability to
take at least 10 steps. Use of assistive devices (e.g., walker or cane) is allowed.

3. Anticipated survival of at least 3 years at the time of Screening, as judged by the
Investigator.

Exclusion Criteria:

1. Any condition that would interfere with the subject's ability to comply with study
instructions, place the subject at unacceptable risk, and/or confound the
interpretation of safety or efficacy data from the study, as judged by the
Investigator.

2. Diagnosis of neurological disorders, other than MSA.